세계의 카포시육종 시장

Global Kaposi Sarcoma Market to Reach US$201.4 Million by 2030

The global market for Kaposi Sarcoma estimated at US$167.0 Million in the year 2024, is expected to reach US$201.4 Million by 2030, growing at a CAGR of 3.2% over the analysis period 2024-2030. HAART, one of the segments analyzed in the report, is expected to record a 3.2% CAGR and reach US$101.5 Million by the end of the analysis period. Growth in the Chemotherapy segment is estimated at 2.5% CAGR over the analysis period.

The U.S. Market is Estimated at US$45.3 Million While China is Forecast to Grow at 3.1% CAGR

The Kaposi Sarcoma market in the U.S. is estimated at US$45.3 Million in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$32.2 Million by the year 2030 trailing a CAGR of 3.1% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 2.9% and 2.6% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 3.4% CAGR.

Global Kaposi Sarcoma Market - Key Trends & Treatment Innovations

Why Is Kaposi Sarcoma a Significant Concern in Oncology?

Kaposi Sarcoma (KS) is a rare form of cancer that develops from the cells that line lymph or blood vessels and is most commonly associated with immunocompromised individuals, particularly those with HIV/AIDS. It manifests as lesions on the skin, but it can also affect internal organs, making it a significant concern in oncology due to its aggressive nature and the complications it can cause. While KS was once considered relatively rare, the rise of the HIV/AIDS epidemic dramatically increased its prevalence, particularly in regions with limited access to antiretroviral therapy (ART). Despite advancements in HIV treatment, Kaposi Sarcoma remains a critical issue, especially in sub-Saharan Africa, where it is one of the most common cancers due to the high rates of HIV infection and limited access to healthcare.

How Are Treatment Approaches for Kaposi Sarcoma Evolving?

Treatment approaches for Kaposi Sarcoma are evolving, driven by advancements in both oncology and HIV/AIDS treatment. The primary treatment for KS involves antiretroviral therapy (ART), which helps control HIV infection and, consequently, can lead to the regression of KS lesions. However, in cases where KS is more aggressive or does not respond adequately to ART, additional treatments such as chemotherapy, radiation therapy, and targeted therapies are employed. Recent developments in targeted therapy and immunotherapy are offering new hope for patients with refractory KS. Drugs that specifically target the molecular pathways involved in KS are showing promise in clinical trials, offering the potential for more effective and less toxic treatments. Moreover, advancements in understanding the role of the human herpesvirus 8 (HHV-8), which is strongly associated with KS, are paving the way for novel therapeutic strategies aimed at preventing or treating this cancer more effectively.

What Challenges Exist in the Treatment and Management of Kaposi Sarcoma?

The treatment and management of Kaposi Sarcoma present several challenges, particularly in resource-limited settings. One of the primary challenges is the early detection and diagnosis of KS, especially in regions where healthcare infrastructure is underdeveloped. Many cases of KS go undiagnosed or are diagnosed at a late stage, when the disease is more difficult to treat. Additionally, the stigma associated with HIV/AIDS can prevent individuals from seeking timely medical care, further complicating the management of KS. Access to treatment is another significant challenge, as many patients in low-income regions do not have access to ART or the necessary oncology care. Furthermore, even in regions with better healthcare infrastructure, there is still a need for more effective therapies with fewer side effects, as current treatment options can be limited in their efficacy and tolerability. Addressing these challenges requires a multifaceted approach, including improving access to ART, enhancing diagnostic capabilities, and developing more effective and accessible treatments.

What Factors Are Driving Research and Treatment Advancements in the Kaposi Sarcoma Market?

The growth in the Kaposi Sarcoma treatment market is driven by several factors, including the ongoing HIV/AIDS epidemic, advancements in cancer research, and the development of targeted therapies. The continuing prevalence of HIV, particularly in regions like sub-Saharan Africa, underscores the need for effective treatments for KS. The expansion of ART programs globally has significantly impacted KS incidence and treatment outcomes, driving demand for integrated HIV and cancer care. Additionally, the progress in cancer research, particularly in understanding the molecular and viral mechanisms underlying KS, is leading to the development of more targeted and effective treatments. The growing interest in immunotherapy and targeted therapies is also contributing to market growth, as these approaches offer new hope for patients with treatment-resistant KS. As research continues and access to advanced treatments improves, the KS treatment market is expected to expand, offering better outcomes for patients worldwide.

SCOPE OF STUDY:

The report analyzes the Kaposi Sarcoma market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Treatment Type (HAART, Chemotherapy, Immunotherapy)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; and Rest of Europe); Asia-Pacific; Rest of World.

Select Competitors (Total 14 Featured) -

• Bristol-Myers Squibb Company
• Eli Lilly and Company
• GlaxoSmithKline PLC
• Johnson & Johnson
• Merck & Co., Inc.
• Pfizer, Inc.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

• 1. MARKET OVERVIEW
  • Influencer Market Insights
  • World Market Trajectories
  • Kaposi Sarcoma - Global Key Competitors Percentage Market Share in 2025 (E)
  • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
  • Global Economic Update
• 2. FOCUS ON SELECT PLAYERS
• 3. MARKET TRENDS & DRIVERS
  • Advancements in Antiretroviral Therapy Expand Treatment Options for Kaposi Sarcoma
  • Increasing Prevalence of HIV/AIDS Propels Demand for Kaposi Sarcoma Therapies
  • Immunotherapy Innovations Strengthen the Business Case for New Treatment Approaches
  • Growing Awareness and Early Detection of Kaposi Sarcoma Throws the Spotlight on Diagnostic Tools
  • Expansion of Cancer Research Funding Accelerates Drug Development for Kaposi Sarcoma
  • Regulatory Approvals for Targeted Therapies Drive Market Growth
  • Shift Towards Combination Therapies Enhances Treatment Efficacy
  • Emerging Markets Present New Opportunities for Kaposi Sarcoma Treatment Providers
  • Clinical Trials and Research Partnerships Propel Innovation in Kaposi Sarcoma Treatments
• 4. GLOBAL MARKET PERSPECTIVE
  • TABLE 1: World Kaposi Sarcoma Market Analysis of Annual Sales in US$ for Years 2015 through 2030
  • TABLE 2: World Recent Past, Current & Future Analysis for Kaposi Sarcoma by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
  • TABLE 3: World Historic Review for Kaposi Sarcoma by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 4: World 15-Year Perspective for Kaposi Sarcoma by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2015, 2025 & 2030
  • TABLE 5: World Recent Past, Current & Future Analysis for HAART by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
  • TABLE 6: World Historic Review for HAART by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 7: World 15-Year Perspective for HAART by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030
  • TABLE 8: World Recent Past, Current & Future Analysis for Chemotherapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
  • TABLE 9: World Historic Review for Chemotherapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 10: World 15-Year Perspective for Chemotherapy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030
  • TABLE 11: World Recent Past, Current & Future Analysis for Immunotherapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
  • TABLE 12: World Historic Review for Immunotherapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 13: World 15-Year Perspective for Immunotherapy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030

III. MARKET ANALYSIS

• UNITED STATES
  • Kaposi Sarcoma Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
  • TABLE 14: USA Recent Past, Current & Future Analysis for Kaposi Sarcoma by Treatment Type - HAART, Chemotherapy and Immunotherapy - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 15: USA Historic Review for Kaposi Sarcoma by Treatment Type - HAART, Chemotherapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 16: USA 15-Year Perspective for Kaposi Sarcoma by Treatment Type - Percentage Breakdown of Value Sales for HAART, Chemotherapy and Immunotherapy for the Years 2015, 2025 & 2030
• CANADA
  • TABLE 17: Canada Recent Past, Current & Future Analysis for Kaposi Sarcoma by Treatment Type - HAART, Chemotherapy and Immunotherapy - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 18: Canada Historic Review for Kaposi Sarcoma by Treatment Type - HAART, Chemotherapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 19: Canada 15-Year Perspective for Kaposi Sarcoma by Treatment Type - Percentage Breakdown of Value Sales for HAART, Chemotherapy and Immunotherapy for the Years 2015, 2025 & 2030
• JAPAN
  • Kaposi Sarcoma Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
  • TABLE 20: Japan Recent Past, Current & Future Analysis for Kaposi Sarcoma by Treatment Type - HAART, Chemotherapy and Immunotherapy - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 21: Japan Historic Review for Kaposi Sarcoma by Treatment Type - HAART, Chemotherapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 22: Japan 15-Year Perspective for Kaposi Sarcoma by Treatment Type - Percentage Breakdown of Value Sales for HAART, Chemotherapy and Immunotherapy for the Years 2015, 2025 & 2030
• CHINA
  • Kaposi Sarcoma Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
  • TABLE 23: China Recent Past, Current & Future Analysis for Kaposi Sarcoma by Treatment Type - HAART, Chemotherapy and Immunotherapy - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 24: China Historic Review for Kaposi Sarcoma by Treatment Type - HAART, Chemotherapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 25: China 15-Year Perspective for Kaposi Sarcoma by Treatment Type - Percentage Breakdown of Value Sales for HAART, Chemotherapy and Immunotherapy for the Years 2015, 2025 & 2030
• EUROPE
  • Kaposi Sarcoma Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
  • TABLE 26: Europe Recent Past, Current & Future Analysis for Kaposi Sarcoma by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
  • TABLE 27: Europe Historic Review for Kaposi Sarcoma by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 28: Europe 15-Year Perspective for Kaposi Sarcoma by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2015, 2025 & 2030
  • TABLE 29: Europe Recent Past, Current & Future Analysis for Kaposi Sarcoma by Treatment Type - HAART, Chemotherapy and Immunotherapy - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 30: Europe Historic Review for Kaposi Sarcoma by Treatment Type - HAART, Chemotherapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 31: Europe 15-Year Perspective for Kaposi Sarcoma by Treatment Type - Percentage Breakdown of Value Sales for HAART, Chemotherapy and Immunotherapy for the Years 2015, 2025 & 2030
• FRANCE
  • Kaposi Sarcoma Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
  • TABLE 32: France Recent Past, Current & Future Analysis for Kaposi Sarcoma by Treatment Type - HAART, Chemotherapy and Immunotherapy - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 33: France Historic Review for Kaposi Sarcoma by Treatment Type - HAART, Chemotherapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 34: France 15-Year Perspective for Kaposi Sarcoma by Treatment Type - Percentage Breakdown of Value Sales for HAART, Chemotherapy and Immunotherapy for the Years 2015, 2025 & 2030
• GERMANY
  • Kaposi Sarcoma Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
  • TABLE 35: Germany Recent Past, Current & Future Analysis for Kaposi Sarcoma by Treatment Type - HAART, Chemotherapy and Immunotherapy - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 36: Germany Historic Review for Kaposi Sarcoma by Treatment Type - HAART, Chemotherapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 37: Germany 15-Year Perspective for Kaposi Sarcoma by Treatment Type - Percentage Breakdown of Value Sales for HAART, Chemotherapy and Immunotherapy for the Years 2015, 2025 & 2030
• ITALY
  • TABLE 38: Italy Recent Past, Current & Future Analysis for Kaposi Sarcoma by Treatment Type - HAART, Chemotherapy and Immunotherapy - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 39: Italy Historic Review for Kaposi Sarcoma by Treatment Type - HAART, Chemotherapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 40: Italy 15-Year Perspective for Kaposi Sarcoma by Treatment Type - Percentage Breakdown of Value Sales for HAART, Chemotherapy and Immunotherapy for the Years 2015, 2025 & 2030
• UNITED KINGDOM
  • Kaposi Sarcoma Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
  • TABLE 41: UK Recent Past, Current & Future Analysis for Kaposi Sarcoma by Treatment Type - HAART, Chemotherapy and Immunotherapy - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 42: UK Historic Review for Kaposi Sarcoma by Treatment Type - HAART, Chemotherapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 43: UK 15-Year Perspective for Kaposi Sarcoma by Treatment Type - Percentage Breakdown of Value Sales for HAART, Chemotherapy and Immunotherapy for the Years 2015, 2025 & 2030
• REST OF EUROPE
  • TABLE 44: Rest of Europe Recent Past, Current & Future Analysis for Kaposi Sarcoma by Treatment Type - HAART, Chemotherapy and Immunotherapy - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 45: Rest of Europe Historic Review for Kaposi Sarcoma by Treatment Type - HAART, Chemotherapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 46: Rest of Europe 15-Year Perspective for Kaposi Sarcoma by Treatment Type - Percentage Breakdown of Value Sales for HAART, Chemotherapy and Immunotherapy for the Years 2015, 2025 & 2030
• ASIA-PACIFIC
  • Kaposi Sarcoma Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
  • TABLE 47: Asia-Pacific Recent Past, Current & Future Analysis for Kaposi Sarcoma by Treatment Type - HAART, Chemotherapy and Immunotherapy - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 48: Asia-Pacific Historic Review for Kaposi Sarcoma by Treatment Type - HAART, Chemotherapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 49: Asia-Pacific 15-Year Perspective for Kaposi Sarcoma by Treatment Type - Percentage Breakdown of Value Sales for HAART, Chemotherapy and Immunotherapy for the Years 2015, 2025 & 2030
• REST OF WORLD
  • TABLE 50: Rest of World Recent Past, Current & Future Analysis for Kaposi Sarcoma by Treatment Type - HAART, Chemotherapy and Immunotherapy - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 51: Rest of World Historic Review for Kaposi Sarcoma by Treatment Type - HAART, Chemotherapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 52: Rest of World 15-Year Perspective for Kaposi Sarcoma by Treatment Type - Percentage Breakdown of Value Sales for HAART, Chemotherapy and Immunotherapy for the Years 2015, 2025 & 2030

IV. COMPETITION